TScan Therapeutics, Inc. 8-K

What Happened TScan Therapeutics, Inc. announced on an 8-K that Vice President of Finance and principal accounting officer Leiden Dworak notified the company on March 31, 2026 that he will resign effective April 10, 2026. The company stated there were no disagreements between Mr. Dworak and TScan regarding operations, policies or practices. The Board appointed Jason A. Amello — the company’s Chief Financial Officer and principal financial officer — to serve as principal accounting officer effective April 10, 2026.

Key Details

• Resignation notice date: March 31, 2026; effective date: April 10, 2026.
• Departing officer: Leiden Dworak, Vice President of Finance and principal accounting officer.
• Successor: Jason A. Amello, current Chief Financial Officer and principal financial officer, appointed principal accounting officer effective April 10, 2026.
• Compensation/agreements: Mr. Amello will receive no additional compensation for the additional role, and no changes were made to plans or arrangements he participates in.
• Additional info: Mr. Amello’s background, business experience and related-party information are incorporated by reference from TScan’s definitive proxy statement on Schedule 14A filed May 14, 2025.

Why It Matters This is an internal leadership change in TScan’s finance function that consolidates the principal accounting officer role with the existing CFO. For investors, the filing signals continuity (no reported disagreements) and no incremental compensation expense tied to the change. The appointment may affect who signs accounting and SEC filings going forward, but the company did not report changes to financial policies or disclosures in this filing.